Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Takeda Aims At BMS’s Sotyktu In $4bn Deal For Nimbus’s TYK2 Inhibitor

$4 billion — Takeda will pay $4bn for Nimbus's Phase IIb TYK2 inhibitor • Source: Shutterstock

Related Content

Gilead Buys Nimbus NASH Drug To Dominate Another Liver Disease

Apr 05 2016

Pharmasset soars on $11B offer, but Gilead investors disturbed

Nov 21 2011

Deal Watch: Aging-Focused Calico Taps Start-Up Terray For Discovery

Oct 13 2022

Nimbus Nips At BMS’s Heels With Psoriasis Results For TYK2 Inhibitor

Nov 30 2022

BMS Aims To Unseat Otezla In Psoriasis With US FDA-Approved Sotyktu

Sep 10 2022

Related Companies

Takeda Pharmaceutical Co. Ltd.

Bristol Myers Squibb Company

Nimbus Therapeutics, Inc.

Gilead Sciences, Inc.

Genentech, Inc.

Eli Lilly and Company

Amgen, Inc.

Pharmasset, Inc.

Additional Topics

M & A Business Strategies Deals Commercial Immune Disorders BioPharmaceutical

More from Deals

More from Business

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window